rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Matthew Gline

CEO

Company insider

Files Form 4 as: CEO, Roivant Sciences.

Every Form 4 they filed

In numbers

Trades disclosed
96
Buys
1
Sells
14
Bought
$50K
Sold
$80.2M
Companies
1
Companies where not an officer
0
First trade
7 Mar 2022
Last trade
30 Sep 2026
Last filed
2 Oct 2026

Companies traded

Where they are an officer
ROIV Roivant SciencesDirector, Officer · Biotechnology · last 30 Sep 20261 buy · 14 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Sep 2026filed 2 Oct 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code F$2.8M76,171 at $36.57filing
30 Jun 2026filed 2 Jul 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code F$2.7M76,171 at $35.39filing
30 Jun 2026filed 2 Jul 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code F$2.7M76,171 at $35.39filing
16 Apr 2026filed 20 Apr 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Sold$8.4M289,774 at $29.16filing
16 Apr 2026filed 20 Apr 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Sold$8.4M289,774 at $29.16filing
31 Mar 2026filed 1 Apr 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code F$8.4M304,684 at $27.70filing
31 Mar 2026filed 1 Apr 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code F$8.4M304,684 at $27.70filing
30 Mar 2026filed 1 Apr 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code M—97,319filing
30 Mar 2026filed 1 Apr 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code F$1.4M53,826 at $26.41filing
30 Mar 2026filed 1 Apr 2026ROIV Roivant Sciencesoption or derivative · BiotechnologySEC FORM 4 Code M$25.0M2,178,150 at $11.50filing
30 Mar 2026filed 1 Apr 2026ROIV Roivant Sciencesoption or derivative · BiotechnologySEC FORM 4 Code M$25.0M2,178,150 at $11.50filing
30 Mar 2026filed 1 Apr 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code M—97,319filing
30 Mar 2026filed 1 Apr 2026ROIV Roivant SciencesBiotechnologySEC FORM 4 Code F$1.4M53,826 at $26.41filing
15 Dec 2025filed 17 Dec 2025ROIV Roivant Sciencesoption or derivative · BiotechnologySEC FORM 4 Code M—234,096 at $0.00filing
15 Dec 2025filed 17 Dec 2025ROIV Roivant Sciencesoption or derivative · BiotechnologySEC FORM 4 Code M—1,363,711 at $0.00filing
15 Dec 2025filed 17 Dec 2025ROIV Roivant Sciencesoption or derivative · BiotechnologySEC FORM 4 Code M—2,272,852 at $0.00filing
15 Dec 2025filed 17 Dec 2025ROIV Roivant SciencesBiotechnologySEC FORM 4 Code M$950K234,096 at $4.06filing
15 Dec 2025filed 17 Dec 2025ROIV Roivant SciencesBiotechnologySEC FORM 4 Sold$5.0M230,357 at $21.68filing
15 Dec 2025filed 17 Dec 2025ROIV Roivant SciencesBiotechnologySEC FORM 4 Code J$81K3,739 at $21.68filing
15 Dec 2025filed 17 Dec 2025ROIV Roivant SciencesBiotechnologySEC FORM 4 Code M$17.3M1,363,711 at $12.68filing

Sectors

Health Care15

Buys in green, sells in red, by the company’s sector.

Related people

Epperly Melissa BDirector · Director at Roivant Sciences, filing Form 4 there in the last year
Frank TortiPresident and Vant Chair · President and Vant Chair at Roivant Sciences, filing Form 4 there in the last year
Eric VenkerChief Executive Officer · President & Immunovant CEO at Roivant Sciences, filing Form 4 there in the last year
Mayukh SukhatmePresident & CIO · President & CIO at Roivant Sciences, filing Form 4 there in the last year
Jennifer HumesChief Accounting Officer · Chief Accounting Officer at Roivant Sciences, filing Form 4 there in the last year
Meghan FitzgeraldDirector · Also traded ROIV in the last 90 days